NASDAQ:IPA
ImmunoPrecise Antibodies seems to be well-positioned to capture potential opportunities in the rapidly expanding AI-driven drug discovery market, seeking to leverage innovative technologies in this transformative space.
Listed on NASDAQ under the ticker IPA, ImmunoPrecise Antibodies seems to be at the forefront of transforming antibody medicine discovery. Leveraging over 60 years of combined expertise, IPA merges artificial intelligence with biotechnology through its proprietary AI software, LENSai, enhanced by their patented HYFT technology. This fusion enables groundbreaking insights into biology, diseases, and medicinal therapies. Serving 19 of the top 20 global pharmaceutical companies, IPA has a client base of over 600, reflecting its pivotal role in the industry.
BioStrand, a subsidiary of ImmunoPrecise Antibodies, announced the immediate commercial release of its groundbreaking LENSai API. This software offers a customizable interface designed for AI-driven drug discovery, marking a significant advancement in the field. BioStrand was honored with the prestigious 2024 Impact Award, sponsored by InterSystems, recognizing its innovative contributions to the biopharmaceutical industry.
The 2024 Impact Award acknowledges BioStrand’s innovative LENSai technology, selected from over 1,000 client projects for its remarkable contributions based on three key criteria:
Current commercial antibodies present a significant challenge in the field, often leading to false findings. A study by the Human Protein Atlas, a Swedish consortium focused on generating antibodies for every human genome protein, examined approximately 20,000 commercial antibodies and found that less than 50% were effective in analyzing protein distribution in preserved tissue samples.
With 80% of life scientists relying on antibodies and spending $3 billion annually on millions of products, the market faces inefficiencies. Large vendors often compete based on catalog size, purchasing antibodies from smaller suppliers, relabeling them, and reselling. According to Bernard, head of Pivotal Scientific, there may be only 250,000–500,000 unique 'core' antibodies among the 2 million on the market. This results in scientists repeatedly testing the same antibodies under different brand names, wasting an estimated $1.5 billion per year.
IPA announced that BioStrand is leveraging their patented Foundation AI Model, LENSai, by applying advanced LLMs to capture real world data from Electronic Health Records (EHR). To be specific, LENSai can significantly enhance the analysis and integration of EHR data, enabling the integrated use of real-world data and evidence in drug discovery and the development of precision medicines (IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)).
IPA announced that its subsidiary BioStrand is collaborating now with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai , to advance the precision medicine field of pharmacogenomics and to support LENSai commercial rollout through expanding LENSai features and market reach.
This marks a significant milestone for the biotechnology industry. Additionally, the antibodies produced by IPA are highly specific to a challenging oncology target located within the Tumor Microenvironment (ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology).
March 20, 2024 IPA announced that it has acquired the LSA® instrument platform from Carterra, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the IPA’s capacity in performing various label-free protein interaction analyses including best-in-class kinetics, epitope binning, quantitation, epitope mapping and blocking/neutralization assays.
Welcome to an exciting era of scientific innovation where the integration of artificial intelligence seems to be reshaping drug discovery and development. ImmunoPrecise Antibodies (NASDAQ: IPA) seeks to position itself at the forefront of this transformation, leveraging over six decades of combined expertise to offer what appears to be innovative solutions in biotechnology. The company’s unique approach, combining AI and antibody medicine discovery, has the potential to lead in this evolving market.
The proprietary LENSai AI software, enhanced by HYFT technology, seeks to provide groundbreaking insights into complex biological systems, with the aim of advancing disease understanding and therapeutic development. Serving 19 of the top 20 global pharmaceutical companies, IPA’s client base highlights the growing recognition of the company’s innovative potential.
With over 80 in silico tools, IPA seeks to revolutionize the conceptualization and delivery of new treatments. The company’s expanding technology suite reflects the broader shift toward AI-driven methodologies in the biopharmaceutical sector.
Financially stable and with no debt, ImmunoPrecise Antibodies appears to be strategically positioned for long-term growth. Its continued focus on innovation could drive significant value for investors.
ImmunoPrecise Antibodies invites stakeholders to explore the company’s potential as it seeks to shape the future of medicine.
Engineering antibodies in silico using LENSai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable.
"This marks a significant milestone for the biotechnology industry, demonstrating LENSai's ability to engineer highly specific and validated antibodies for the exceedingly difficult environment around tumors, and doing so entirely on a computer," "This success, elevated by the fact that important details of the protein being targeted were unknown, represents a major feat in the application of LENSai in generating targeted and specific therapies for the potential treatment of cancer. Moreover, immunoPrecise continuous advancements and integrations have significantly enhanced ImmunoPrecise ability to develop these therapies faster, more efficiently, and at a reduced cost compared to traditional methods."
IPA (1983, Canada) is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry’s most trusted independent market research sources with the highest competitive score for its antibody service portfolio.
The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. They provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services (Talem)—with advanced omics and complex intelligence technology (LENSᵃⁱ) that provide greater efficiency and accuracy than ever before. Talem Therapeutics LLC is also a subsidiary of IPA and is focused on the discovery and development of next-generation, human, monoclonal, therapeutic antibodies.
Reduce the risk, time, and cost associated with antibody discovery, ultimately leading to safer and more effective therapies that reach patients faster and provide unparalleled value for partners and investors.
In 2018, the company began an ambitious transformation, including strategic investments into technology-focused R&D and acquisitions
Best-in-class high-throughput single B cell analysis that directly extracts the DNA sequences of antibodies with KNOWN FUNCTIONS, representing potentially life-saving therapies.
LENSai from BioStrand (an IPA subsidiary) unprecedented software that, through patented pattern recognition (in DNA, RNA or protein sequences or structures), can extract meaningful insights for drug discovery from any type of data, instantaneously, using very little energy and at an unlimited scale.
Industry-leading laboratory technologies enable clinically validated, large-scale sequences and functional data, analyzed in a scalable cloud repository.
Acclaimed by independent leader in pharmaceutical market research: Roots Analysis
Best-in-class end-to-end discovery, development, and manufacturing services bolstered with our revolutionary and patented AI technology.
25 billion relationships is foundation for de novo discovery.
Represents years' worth of traditional research, in minutes.
Cutting-edge patented algorithm identifies sequence and structural patterns in biosphere
Highlighting strong performance and ability to drive innovation and efficiency across all operations
ImmunoPrecise Antibodies stands at the forefront of the biopharmaceutical landscape, leveraging innovative technologies to transform antibody discovery. The company’s proprietary LENSai platform, enhanced by AI capabilities, positions it to address critical needs within the market.
With a robust financial performance, FY24 revenues reached C$24.5 million, reflecting a 19% increase year-over-year. This growth is driven by strong demand for its B Cell Select platform and advanced VHH antibody discovery technologies.
The anticipated expansion of the global AI in drug discovery market presents significant opportunities for ImmunoPrecise. Projected to reach $11.93 billion by 2033, this sector aligns with the company’s strategic vision and offerings.
Furthermore, ImmunoPrecise's operational efficiency is highlighted by a notable reduction in R&D expenses, enabling reinvestment in core technologies.
As the company continues to evolve, it remains a compelling prospect for investors seeking to capitalize on the dynamic biopharmaceutical market.
PLEASE NOTE WELL: Delta3 AI are not registered as an Investment Advisor in any jurisdiction whatsoever.
This is for informational purposes only. Delta3 AI LLC has not been compensated for this this profile (IPA).
Stocks profiled on Delta3 AI web site are for informational purposes only. Information on these pages contains forward – looking statements that involve risk and uncertainties. The purpose of these profiles is to make investors aware of these companies and should not in any way come across as a recommendation to buy or sell in these securities. Investing in stocks involves risk. You should consult a qualified financial advisor or broker before making any investment decisions. All profiles are based on information that is available to the public. Past performance of stocks profiled on this web site is not a guarantee as to future performance. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Delta3 AI to be free from misstatements or errors.
We do not give price targets in any of our written or recorded material.
Please do your own research and make your own investment decisions. Always remember that Delta3 AI is not an analyst and we do not employ or contract any analysts. Investing in securities such as the ones mentioned on our website, in email, or consulted for are for high-risk tolerant individuals only and not the general public.
Whether you are an experienced penny stocks investor or not, you should always consult with a licensed penny stock broker before buying or selling any securities that Delta3 AI profiles, mentions, in email updates, consults for or interviews. If shares are restricted, Delta3 AI may sell them when they are registered. If the penny stocks shares are freely transferable, Delta3 AI intends to sell them. At no time will any Delta3 AI employees or affiliates undertake any activity that could be regarded in any fashion as improper or illegal. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
Many of the companies communicated in our emails or website are developmental stage companies with little or no operating or trading history. The information contained in our alerts should be viewed as commercial advertisement and is not intended to be investment opinion. The report is not provided to any particular individual with a view toward their investment circumstances. The information contained in our alerts is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge to individuals who wish to receive them. Our advertisements and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiles based solely on information contained in our report. Individuals should assume that all information contained in the alerts about profiled companies is not trust worthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some of all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing. The profiles are a service of Delta3 AI, a marketing and advertising firm that may have been compensated. All direct and third party compensation received will be disclosed within each individual alert in accordance with section 17(b) of the nineteen thirty three Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Delta3 AI distributes its Electronic Content and provides other promotional services with the intention of helping the “featured company and or companies” to create public awareness of their current business and future objectives, as well as to aid in the development of a liquid trading market for the “featured company’s” securities, although there is no intent to make a market or facilitate, in any manner, the purchase and sale of the “featured company and or companies” securities. Electronic Content refers to all Electronic Material distributed and created, and/or edited by Delta3 AI and includes, but is not limited to Emails, Newsletters, any Social Media content such as Facebook and Twitter, Blog Postings, Video Content, Corporate Profiles, Corporate Videos, Analyst Reports, PowerPoint Presentations, CEO Video Interviews, Press releases, Banners, Images, Google Advertising, Microsoft Ad center Advertising, and/or web based discussion board postings of any kind.
Although there is no guarantee that a liquid market will develop in the “featured company’s” securities, in the event that an active market does develop, investors should be aware that existing shareholders (controlling, or non-controlling) will be motivated to sell their shares potentially creating an oversupply scenario, under which the price of the shares is likely to experience sudden declines. At the same time, if the existing shareholder base holds shares tightly, and an active trading market develops, this may result in sudden increases in the price of the stock due to a potential undersupply scenario. In any case, there can be no guarantee that the price of the stock will reflect the fundamental value of the “featured company and or companies”. Delta3 AI disclaims all knowledge of the “featured company and/or companies” shareholder base, capacity for liquidity, or other means or methods of enhancing public awareness.
Forward Looking Statements
All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell penny stocks securities of the penny stocks companies profiled herein and any decision to invest in any such penny stocks company or other financial decisions should not be made based upon the information provide herein. Instead Delta3 AI strongly urges you to conduct a complete due diligence of the respective penny stocks companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Delta3 AI does not offer such advice or analysis, and Delta3 AI urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth penny stocks securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
Delta3 AI may feature or profile a company periodically (usually for life of contract) and may remove that profile at it’s own discretion. Profiles and disclosures for those profiles may or may not remain visible on Delta3 AI website.
Delta3 AI website may contain links to related websites including, but not limited to, stock charts, stock quotes, SEC data, NASD data, etc. We are not responsible for the content of or the privacy practices used by these sites. We encourage our readers to review all public filings by companies at the SEC’s EDGAR page located at SEC.gov. The Delta3 AI has published information on how to invest carefully at NASD.com.
PLEASE READ CAREFULLY - Delta3 AI is engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Delta3 AI sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Delta3 AI or an offer or solicitation to buy or sell any security. Neither the owner of Delta3 AI nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters . Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk.
Notice of Stock Price Movements and Volatility Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week. Some of the content in this release contains forward-looking information within the meaning of Section 27 A of the Securities Act of 1 993 and Section 21 E of the Securities Exchange Act of 1 934 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1 995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable.
Delta3 AI makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Delta3 AI Network has no obligation to update any of the information provided. Delta3 AI, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our release or on our website may not have approved certain or any statements within the website. Delta3 AI encourages viewers to supplement the information obtained from this release and our website with independent research and other professional advice. The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.
This release may provide hyperlinks to third party websites or access to third party content. Delta3 AI its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Delta3 AI control, endorse, or guarantee any content found in such sites. By accessing, viewing, or using the website or communications originating from this release, you agree that Delta3 AI its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Delta3 AI, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
Delta3 AI uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold Delta3 AI its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. Delta3 AI disclaims all warranties of any kind, express or implied. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.
(Last updated: )